Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2014; 63: 2935-2959
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Hypertension. 2017; (HYP.0000000000000066)
- 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2014; 63: 2889-2934
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Am Coll Cardiol. 2019; 73: 3168-3209
- Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension.J Am Coll Cardiol. 2018; 71: 1601-1610
- Comparison of frequency of atherosclerotic cardiovascular and safety events with systolic blood pressure <120 mm hg versus 135-139 mm hg in a Systolic Blood Pressure Intervention Trial primary prevention subgroup.Am J Cardiol. 2018; 122: 1185-1190
- Systolic Blood Pressure Intervention Trial (SPRINT): Protocol Version 4.0.2012 (Available at:)Accessed June 14, 2018)
- A randomized trial of intensive versus standard blood-pressure control.N Engl J Med. 2015; 373: 2103-2116
- Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis.Springer, Switzerland2015
- Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.JAMA. 2007; 297: 611-619
- C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.Circulation. 2008; 118 (4p following 2251): 2243-2251
- Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.BMJ. 2017; 357: j2099
- Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC).Heart Br Card Soc. 2007; 93: 172-176
- Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations.JAMA. 2014; 311: 1406-1415
- A general cardiovascular risk profile: the Framingham Study.Am J Cardiol. 1976; 38: 46-51
- An updated coronary risk profile. A statement for health professionals.Circulation. 1991; 83: 356-362
- Utility of the Framingham Risk score in predicting secondary events in patients following percutaneous coronary intervention: a time-trend analysis.Am Heart J. 2016; 172: 115-128
- Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score.Heart Br Card Soc. 2013; 99: 866-872
- Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population.Circulation. 2016; 134: 1419-1429
Suggested Tweet: Prior CVD is a major risk for subsequent events in SPRINT, even when accounting for baseline Pooled Cohort Equation-predicted risk.
Funding: This work was sponsored by the Department of Medicine at the Larner College of Medicine. SPJ is sponsored by an NHLBI career development award (K23HL135273), Boston, MA.